Skip to main navigation Skip to main content

Page translation not available

This page is not available in the language that has been selected and will appear in English.

Search

Contact us

07 3737 4500

PO Box 3787

South Brisbane QLD 4101
Become a patient

Dr Stanley Cheung

MBBS, PhD, MRCP, FRACP, FHKCP, FHKAM, FRCP (Glasg)

  • Clinical Haematologist
Become a patient Refer a patient
Adelaide
08 8474 0220 08 8450 3375
admin.adelaide@icon.team

Biography

Dr Stanley Cheung is a clinical haematologist at Icon Cancer Centre Adelaide and Icon Cancer Centre Windsor Gardens. He is a medical graduate from the University of Hong Kong and in 2005 obtained his FHKCP in Haematology following post-graduate training in Hong Kong and Adelaide.

He moved to Adelaide in 2008 and studied his PhD with the international expert in chronic myeloid leukemia (Professor Junia V Melo) and subsequently worked as a full-time research fellow/postdoc fellow in Royal Adelaide Hospital and SAHMRI (South Australia Health and Medical Research Institute) from 2013. Dr Cheung is experienced in caring for a wide range of malignant and non-malignant haematological conditions, with particular interest in leukaemia, lymphoma, multiple myeloma, thrombosis and haemostasis.

He speaks fluent Cantonese and limited Mandarin and looks forward to caring for patients in a language they are familiar with.

Research

Trials being conducted by this doctor

MRDR

This observational study is collecting information from patients to form the Myeloma and Related Diseases Registry (MRDR).

Locations Adelaide, Wesley

Diagnosis Multiple myeloma

Open for recruitment

BBI-TP-3654-102

This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.Arm 1 will enroll patients who have been previously treated and failed on a JAK inhibitor or ineligible to receive treament with a JAK inhibitor.Arm 2 will enroll patients who are on a stable dose of ruxolitinib, but who have either lost response or had a suboptimal or plateau in response.Arm 3 will enroll patients who have been previously treated on JAK inhibitor (except momelotinib) that was complicated by anemia, thrombocytopenia or hematoma.

Locations Windsor Gardens

Diagnosis Myeloproliferative disorders

Open for recruitment
See all trials by Dr Stanley Cheung